Compare PSMT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSMT | VKTX |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.8B |
| IPO Year | 1997 | 2015 |
| Metric | PSMT | VKTX |
|---|---|---|
| Price | $140.44 | $34.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $87.07 |
| AVG Volume (30 Days) | 221.2K | ★ 3.3M |
| Earning Date | 01-07-2026 | 02-04-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 7.94 | N/A |
| EPS | ★ 4.90 | N/A |
| Revenue | ★ $5,394,879,000.00 | N/A |
| Revenue This Year | $10.66 | N/A |
| Revenue Next Year | $9.64 | N/A |
| P/E Ratio | $28.75 | ★ N/A |
| Revenue Growth | ★ 7.78 | N/A |
| 52 Week Low | $81.25 | $18.92 |
| 52 Week High | $143.37 | $43.15 |
| Indicator | PSMT | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 76.38 | 49.82 |
| Support Level | $134.43 | $29.54 |
| Resistance Level | $143.37 | $36.00 |
| Average True Range (ATR) | 4.43 | 1.98 |
| MACD | 1.51 | -0.02 |
| Stochastic Oscillator | 89.45 | 59.83 |
Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.